$115.91
0.590.51%
At close: -
$115.91
0.000.00%
After Hours: 4:33 PM EDT
Comments
Loading...
Encompass Health Analyst Ratings and Price Targets | NYSE:EHC | Benzinga
Encompass Health Corp has a consensus price target of $94.71 based on the ratings of 17 analysts. The high is $135 issued by Truist Securities on April 28, 2025. The low is $57 issued by Barclays on March 14, 2023. The 3 most-recent analyst ratings were released by UBS, RBC Capital, and Truist Securities on April 28, 2025, respectively. With an average price target of $130 between UBS, RBC Capital, and Truist Securities, there's an implied 12.16% upside for Encompass Health Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
RBC Capital
Truist Securities
Keybanc
Barclays
1calculated from analyst ratings
Analyst Ratings for Encompass Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/28/2025 | Buy Now | 12.16% | UBS | Andrew Mok54% | $117 → $130 | Maintains | Buy | Get Alert |
| 04/28/2025 | Buy Now | 7.84% | RBC Capital | Ben Hendrix58% | $110 → $125 | Maintains | Outperform | Get Alert |
| 04/28/2025 | Buy Now | 16.47% | Truist Securities | David Macdonald64% | $116 → $135 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2025 | Buy Now | 5.25% | Keybanc | Matthew Gillmor63% | $120 → $122 | Maintains | Overweight | Get Alert |
| 04/25/2025 | Buy Now | 11.29% | Barclays | Andrew Mok54% | $118 → $129 | Maintains | Overweight | Get Alert |
| 02/11/2025 | Buy Now | -5.1% | RBC Capital | Ben Hendrix58% | $110 → $110 | Reiterates | Outperform → Outperform | Get Alert |
| 02/10/2025 | Buy Now | 3.53% | Keybanc | Matthew Gillmor63% | $117 → $120 | Maintains | Overweight | Get Alert |
| 02/07/2025 | Buy Now | 1.8% | Barclays | Andrew Mok54% | $116 → $118 | Maintains | Overweight | Get Alert |
| 10/30/2024 | Buy Now | -5.1% | RBC Capital | Ben Hendrix58% | $105 → $110 | Maintains | Outperform | Get Alert |
| 10/30/2024 | Buy Now | 0.08% | Truist Securities | David Macdonald64% | $108 → $116 | Reiterates | Buy → Buy | Get Alert |
| 10/29/2024 | Buy Now | 0.08% | Barclays | Andrew Mok54% | $109 → $116 | Maintains | Overweight | Get Alert |
| 10/29/2024 | Buy Now | 0.94% | Keybanc | Matthew Gillmor63% | $115 → $117 | Maintains | Overweight | Get Alert |
| 10/14/2024 | Buy Now | -6.82% | Truist Securities | David Macdonald64% | $104 → $108 | Maintains | Buy | Get Alert |
| 10/11/2024 | Buy Now | -0.79% | Keybanc | Matthew Gillmor63% | → $115 | Initiates | → Overweight | Get Alert |
| 09/26/2024 | Buy Now | -9.41% | RBC Capital | Ben Hendrix58% | $95 → $105 | Maintains | Outperform | Get Alert |
| 09/25/2024 | Buy Now | -5.1% | UBS | Andrew Mok54% | $100 → $110 | Maintains | Buy | Get Alert |
| 08/15/2024 | Buy Now | -10.28% | Truist Securities | David Macdonald64% | $100 → $104 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | -13.73% | UBS | Andrew Mok54% | $96 → $100 | Maintains | Buy | Get Alert |
| 08/06/2024 | Buy Now | -9.41% | Stephens & Co. | Scott Fidel69% | $105 → $105 | Reiterates | Overweight → Overweight | Get Alert |
| 08/06/2024 | Buy Now | -5.96% | Barclays | Andrew Mok54% | $113 → $109 | Maintains | Overweight | Get Alert |
| 07/15/2024 | Buy Now | -13.73% | Truist Securities | David Macdonald64% | $95 → $100 | Maintains | Buy | Get Alert |
| 07/10/2024 | Buy Now | -2.51% | Barclays | Andrew Mok54% | $108 → $113 | Maintains | Overweight | Get Alert |
| 07/10/2024 | Buy Now | -13.73% | Leerink Partners | Whit Mayo66% | → $100 | Initiates | → Outperform | Get Alert |
| 06/05/2024 | Buy Now | -18.9% | Stephens & Co. | Scott Fidel69% | $94 → $94 | Reiterates | Overweight → Overweight | Get Alert |
| 05/22/2024 | Buy Now | -18.04% | RBC Capital | Ben Hendrix58% | $83 → $95 | Maintains | Outperform | Get Alert |
| 04/26/2024 | Buy Now | -18.04% | Raymond James | John Ransom76% | $85 → $95 | Reiterates | Strong Buy → Strong Buy | Get Alert |
| 04/25/2024 | Buy Now | -6.82% | Barclays | Andrew Mok54% | $101 → $108 | Maintains | Overweight | Get Alert |
| 04/25/2024 | Buy Now | -18.04% | Mizuho | Ann Hynes85% | $93 → $95 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | -12.86% | Barclays | Andrew Mok54% | $95 → $101 | Maintains | Overweight | Get Alert |
| 03/06/2024 | Buy Now | -18.04% | Barclays | Andrew Mok54% | → $95 | Initiates | → Overweight | Get Alert |
| 02/09/2024 | Buy Now | -28.39% | RBC Capital | Ben Hendrix58% | $83 → $83 | Reiterates | Outperform → Outperform | Get Alert |
| 02/09/2024 | Buy Now | -25.8% | Truist Securities | David Macdonald64% | $82 → $86 | Maintains | Buy | Get Alert |
| 02/09/2024 | Buy Now | -29.26% | Mizuho | Ann Hynes85% | $77 → $82 | Maintains | Buy | Get Alert |
| 01/16/2024 | Buy Now | -26.67% | Stephens & Co. | Scott Fidel69% | $85 → $85 | Reiterates | Overweight → Overweight | Get Alert |
| 09/28/2023 | Buy Now | -28.39% | RBC Capital | Ben Hendrix58% | → $83 | Reiterates | Outperform → Outperform | Get Alert |
| 08/08/2023 | Buy Now | -28.39% | RBC Capital | Ben Hendrix58% | $70 → $83 | Maintains | Outperform | Get Alert |
| 08/04/2023 | Buy Now | -39.61% | Barclays | Jason Goldberg56% | $61 → $70 | Maintains | Equal-Weight | Get Alert |
| 08/04/2023 | Buy Now | -30.98% | Credit Suisse | Jonathan Yong66% | $76 → $80 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | -26.67% | Raymond James | John Ransom76% | $80 → $85 | Maintains | Strong Buy | Get Alert |
| 08/03/2023 | Buy Now | -29.26% | Truist Securities | David Macdonald64% | $75 → $82 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -33.57% | Mizuho | Ann Hynes85% | $74 → $77 | Maintains | Buy | Get Alert |
| 08/03/2023 | Buy Now | -38.75% | Barclays | Jason Goldberg56% | $61 → $71 | Maintains | Equal-Weight | Get Alert |
| 07/20/2023 | Buy Now | -32.71% | Stephens & Co. | Scott Fidel69% | → $78 | Reiterates | Overweight → Overweight | Get Alert |
| 06/29/2023 | Buy Now | -32.71% | Stephens & Co. | Scott Fidel69% | $74 → $78 | Maintains | Overweight | Get Alert |
| 05/02/2023 | Buy Now | -39.61% | RBC Capital | Ben Hendrix58% | $66 → $70 | Maintains | Outperform | Get Alert |
| 05/02/2023 | Buy Now | -30.98% | Raymond James | John Ransom76% | $72 → $80 | Maintains | Strong Buy | Get Alert |
| 05/01/2023 | Buy Now | -37.02% | Deutsche Bank | Pito Chickering67% | $70 → $73 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | -36.16% | Stephens & Co. | Scott Fidel69% | $70 → $74 | Maintains | Overweight | Get Alert |
| 05/01/2023 | Buy Now | -34.43% | Credit Suisse | Jonathan Yong66% | $73 → $76 | Maintains | Outperform | Get Alert |
| 05/01/2023 | Buy Now | -36.16% | Mizuho | Ann Hynes85% | $69 → $74 | Maintains | Buy | Get Alert |
| 04/28/2023 | Buy Now | -36.16% | B of A Securities | Kevin Fischbeck67% | $69 → $74 | Maintains | Buy | Get Alert |
| 04/04/2023 | Buy Now | -47.37% | Barclays | Jason Goldberg56% | $57 → $61 | Maintains | Equal-Weight | Get Alert |
| 03/14/2023 | Buy Now | -50.82% | Barclays | Steve Valiquette54% | → $57 | Initiates | → Equal-Weight | Get Alert |
| 02/09/2023 | Buy Now | -35.29% | Truist Securities | David Macdonald64% | $70 → $75 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | -37.02% | Credit Suisse | A.J. Rice69% | $62 → $73 | Maintains | Outperform | Get Alert |
| 02/09/2023 | Buy Now | -40.47% | Mizuho | Ann Hynes85% | $65 → $69 | Maintains | Buy | Get Alert |
| 02/08/2023 | Buy Now | -39.61% | Stephens & Co. | Scott Fidel69% | → $70 | Maintains | Overweight | Get Alert |
| 10/28/2022 | Buy Now | -49.96% | Stephens & Co. | Scott Fidel69% | $60 → $58 | Maintains | Overweight | Get Alert |
| 10/28/2022 | Buy Now | -37.88% | Raymond James | John Ransom76% | $65 → $72 | Maintains | Strong Buy | Get Alert |
| 09/21/2022 | Buy Now | -46.51% | Credit Suisse | A.J. Rice69% | $63 → $62 | Maintains | Outperform | Get Alert |
| 08/24/2022 | Buy Now | -43.06% | RBC Capital | Ben Hendrix58% | $82 → $66 | Maintains | Outperform | Get Alert |
| 08/08/2022 | Buy Now | -43.92% | Truist Securities | David Macdonald64% | $75 → $65 | Maintains | Buy | Get Alert |
| 08/04/2022 | Buy Now | -43.92% | BMO Capital | Matt Borsch77% | $83 → $65 | Maintains | Outperform | Get Alert |
| 08/04/2022 | Buy Now | -43.92% | Raymond James | John Ransom76% | $70 → $65 | Maintains | Strong Buy | Get Alert |
| 08/04/2022 | Buy Now | -45.65% | Barclays | Steve Valiquette54% | $80 → $63 | Maintains | Overweight | Get Alert |
| 06/21/2022 | Buy Now | -35.29% | Truist Securities | David Macdonald64% | $85 → $75 | Maintains | Buy | Get Alert |
| 06/21/2022 | Buy Now | -36.16% | Stephens & Co. | Scott Fidel69% | $78 → $74 | Maintains | Overweight | Get Alert |
| 06/17/2022 | Buy Now | -39.61% | Raymond James | John Ransom76% | $85 → $70 | Maintains | Strong Buy | Get Alert |
| 06/10/2022 | Buy Now | -29.26% | Credit Suisse | Nick Giovacchini50% | $83 → $82 | Maintains | Outperform | Get Alert |
| 06/08/2022 | Buy Now | -29.26% | RBC Capital | Ben Hendrix58% | $85 → $82 | Maintains | Outperform | Get Alert |
| 05/03/2022 | Buy Now | -26.67% | RBC Capital | Ben Hendrix58% | $104 → $85 | Maintains | Outperform | Get Alert |
| 05/02/2022 | Buy Now | -26.67% | Raymond James | John Ransom76% | $80 → $85 | Maintains | Strong Buy | Get Alert |
| 04/29/2022 | Buy Now | -28.39% | Credit Suisse | Jonathan Yong66% | $82 → $83 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Encompass Health (EHC) stock?
The latest price target for Encompass Health (NYSE:EHC) was reported by UBS on April 28, 2025. The analyst firm set a price target for $130.00 expecting EHC to rise to within 12 months (a possible 12.16% upside). 25 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Encompass Health (EHC)?
The latest analyst rating for Encompass Health (NYSE:EHC) was provided by UBS, and Encompass Health maintained their buy rating.
When was the last upgrade for Encompass Health (EHC)?
There is no last upgrade for Encompass Health
When was the last downgrade for Encompass Health (EHC)?
There is no last downgrade for Encompass Health.
When is the next analyst rating going to be posted or updated for Encompass Health (EHC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Encompass Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Encompass Health was filed on April 28, 2025 so you should expect the next rating to be made available sometime around April 28, 2026.
Is the Analyst Rating Encompass Health (EHC) correct?
While ratings are subjective and will change, the latest Encompass Health (EHC) rating was a maintained with a price target of $117.00 to $130.00. The current price Encompass Health (EHC) is trading at is $115.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
